Abstract | BACKGROUND: METHODS: The study population consisted of 70 patients with advanced colorectal cancer (median age, 54 years). Patients were treated with oxaliplatin 85 mg/m as a 2-hour infusion on days 1 plus leucovorin (LV) 20 mg/m over 10 minutes, followed by 5-FU bolus 400 mg/m and a 22-hour continuous infusion of 600 mg/m from day 1 to 2. Treatment was repeated at 2-week intervals. The expression of ERCC1, TS, and GSTpi in primary tumors was examined using immunohistochemistry. RESULTS: ERCC1, TS, and GSTpi were positive in 55.7%, 68.6%, and 71.4% of cases, respectively. Patients without TS expression were more likely to respond to chemotherapy (P = 0.009). There were no significant differences between response to treatment and the ERCC1 or GSTpi expression pattern (P = 0.768, P = 0.589, respectively). The median overall survival (OS) was significantly longer in patients without ERCC1 expression (P = 0.0474). Patients who were ERCC1 positive combined with TS positive, or those with ERCC1 positive combined with TS positive and GSTpi positive had a poor OS (P = 0.0017, P = 0.0323, respectively). Multivariate analysis revealed that both ERCC1 and TS expression significantly impacted OS (hazard ratio 1.72, P = 0.023). CONCLUSION: Immunohistochemical study of ERCC1 and TS may be useful for the prediction of clinical outcome in patients with advanced colorectal cancer treated with 5-FU and oxaliplatin.
|
Authors | Sung-Hyun Kim, Hyuk-Chan Kwon, Sung Yong Oh, Dong Mee Lee, Suee Lee, Jong-Hoon Lee, Mee-Sook Roh, Dae-Cheol Kim, Ki-Jae Park, Hong-Jo Choi, Hyo-Jin Kim |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 32
Issue 1
Pg. 38-43
(Feb 2009)
ISSN: 1537-453X [Electronic] United States |
PMID | 19194123
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- DNA-Binding Proteins
- Organoplatinum Compounds
- Oxaliplatin
- Thymidylate Synthase
- GSTP1 protein, human
- Glutathione S-Transferase pi
- ERCC1 protein, human
- Endonucleases
- Fluorouracil
|
Topics |
- Adenocarcinoma
(drug therapy, enzymology, secondary)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(metabolism)
- Colorectal Neoplasms
(drug therapy, enzymology, pathology)
- DNA Repair
- DNA-Binding Proteins
(metabolism)
- Endonucleases
(metabolism)
- Female
- Fluorouracil
(administration & dosage)
- Follow-Up Studies
- Glutathione S-Transferase pi
(metabolism)
- Humans
- Immunoenzyme Techniques
- Liver Neoplasms
(drug therapy, enzymology, secondary)
- Lung Neoplasms
(drug therapy, enzymology, secondary)
- Lymphatic Metastasis
- Male
- Middle Aged
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Peritoneal Neoplasms
(drug therapy, enzymology, secondary)
- Prognosis
- Retrospective Studies
- Survival Rate
- Thymidylate Synthase
(metabolism)
- Treatment Outcome
|